letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7212 News 


«12...3536373839404142434445...100101»
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Combined treatment of letrozole or olaparib with aspirin inhibits cell proliferation and induces apoptosis through upregulation of wild p53 and modulation of aurora kinases in human breast cancer cell lines (Section 5) -  Mar 9, 2022 - Abstract #AACR2022AACR_2848;    
    Interestingly, in T-47D cells, combined treatment of Letrozole with Aspirin significantly upregulated wild p53 at protein level and downregulated CYP1A1, CYP1B1, Aurora-A, and Aurora-B expression at gene level compared to control, suggesting that combined treatment may inhibit breast cancer cell proliferation via down-regulation of Aurora-A and Aurora-B. In MDA-MB-231 cells, combined treatment of Olaparib with Aspirin showed a significant downregulation of Mutant p53 at protein level and CYP1A1, CYP1B1, Aurora-B and upregulation of Aurora-A at gene level compared to control, suggesting that there is a crosstalk between Olaparib/ Aspirin and P53In conclusion, combined treatment of Letrozole or Olaparib with Aspirin might be a promising approach to inhibit both ER (+) and triple negative breast cancer cell lines survival and proliferation.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Tecentriq (atezolizumab) / Roche
    Gender and estrogens as key factors in the response to immunotherapy in non small cell lung cancer (New Orleans Theater A, Convention Center) -  Mar 9, 2022 - Abstract #AACR2022AACR_1928;    
    These changes increased plasma-membrane fluidity, an event that in turns reduced the affinity between PD-L1 and PD-1. As further proof of concept, ω6- or ω3-PUFA treated cells, displayed an increased membrane fluidity and a change in lipid metabolism that affect the response to anti-PD-1/PD-L1 as letrozole did.We propose a prototypical in vitro 3D spheroids culture gender-tailored platform that allows to investigate the metabolic circuitries causing such differences and to repurpose metabolic modifiers as novel immune-adjuvant agents in oncology.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Effectiveness of Short Term Neoadjuvant Endocrine Therapy on KI67 in Luminal Breast Cancers (Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1438;    
    Short-term changes in Ki67 index in the neoadjuvant settings may predict outcome during adjuvant use of same treatment. The data indicate that tamoxifen may not be an effective choice of therapy in neoadjuvant setting, wherein letrozole has a marked effectiveness in preoperative therapy in patients with ER/PR positive untreated breast cancer.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Evaluation of the Behavior of the Dispensing of Drugs for Breast Cancer in a Cohort of Patients in Colombia (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_448;    
    The total cohort had 3,076 patients dispensed since January 1, 2020, 22.5% of the patients had up to 4 treatments delivered in the analysis period, the treatment with the highest dispensation was Anastrozole in 29.5%, followed by Letrozole 23.3% used in initial lines of treatment. A trend is observed in the use of low-cost medications in the analysis cohort that is maintained during follow-up, however, the cost differential in the lines of treatment analyzed is high, therefore, timely treatment would generate savings associated with use of first-line treatments.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  AMICA: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Mar 8, 2022   
    P2,  N=150, Active, not recruiting, 
    Further analysis is necessary to better understand management decisions for this group of patients cared for within CHS. Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jul 2022
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  NEOLBC: Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (clinicaltrials.gov) -  Mar 7, 2022   
    P2,  N=100, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2022 --> Jul 2022 Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Dec 2021 --> Mar 2026
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Ribociclib-Induced Pseudo-Acute Kidney Injury () -  Mar 6, 2022 - Abstract #NKFSCM2022NKF_SCM_670;    
    Ribociclib inhibits OCT2 and MATE 1, thereby interfering with creatinine secretion. CONCLUSION Recognizing the underlying reason for elevated creatinine in patients on chemotherapeutic agents can help avoid unnecessary or premature discontinuation of these effective therapies.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Review, Journal:  Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis. (Pubmed Central) -  Mar 3, 2022   
    There is no evidence that letrozole increases the risk of congenital foetal malformation or pregnancy loss compared with clomiphene, natural conception or other fertility agents, to warrant warning against its use. Given its therapeutic benefits and lack of evidence of harm to the foetus, clinicians should consider letrozole as first-line agent for ovulation induction.
  • ||||||||||  letrozole / Generic mfg.
    Journal, IO biomarker:  Involvement of endometrial IGF-1R/IGF-1/Bcl-2 pathways in experimental polycystic ovary syndrome: Identification of the regulatory effect of melatonin. (Pubmed Central) -  Mar 3, 2022   
    Thirty-two 6-8 week old Sprague Dawley rats were divided into four groups: the Sham Control Group (1% CMC/day by oral gavage [o.g.]); the Melatonin Group (2 mg/kg/day melatonin by subcutaneous administration [s.c.]); the Experimental PCOS Group (1 mg/kg/day Letrozole by o.g.); and the Experimental PCOS + Melatonin Group (1 mg/kg/day Letrozole by o.g. and 2 mg/kg/day melatonin by s.c. administration)...Morphological degenerations returned to its normal appearance generally by the melatonin administrations and melatonin also regulated the increased expression of endometrial IGF-1R/IGF-1/Bcl-2 and PCNA pathways. It is concluded that additional studies are needed, using melatonin as a supporting agent may be appropriate in cases of PCOS.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Clinical, Journal:  Clinical application of aromatase inhibitors to treat male infertility. (Pubmed Central) -  Mar 3, 2022   
    This narrative review has summarized the target patients, dose, treatment duration and side-effects of AIs. Polymorphisms of CYP19A1 that may affect AIs treatment efficacy were also summarized, but a full understanding of the mechanisms involved in AIs action requires further study.
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Journal:  Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients. (Pubmed Central) -  Mar 3, 2022   
    With adjustment for significant between-group baseline differences using multivariable logistic generalized estimating equation model analyses, there was no statistical difference in oocytes retrieved and embryo development between the study and control groups, and insignificant increases in successful pregnancies in the study group were found compared to the control group (i.e., odds ratios [95% CIs]: 1.13 [0.55, 232] and 1.50 [0.65, 3.49] for ongoing pregnancy and live birth, respectively). For POSEIDON Group 4 patients, cotreatment of CC and letrozole in mild stimulation may increase the high-quality oocyte ratio and yield comparable fertilization rate and pregnancy outcomes.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effects of neural-derived estradiol on actin polymerization and synaptic plasticity-related proteins in prefrontal and hippocampal cells of mice. (Pubmed Central) -  Mar 1, 2022   
    Primary cultured hippocampal and prefrontal cells in mice were randomly divided into the DMSO (D), aromatase (Rate-limiting enzymes for E2 synthesizes) inhibitor letrozole (L), and ERs antagonist (MPG) treated groups...In conclusion, neural-derived E2 and ERs regulated the synaptic plasticity, possibly due to promoting actin polymerization in prefrontal and hippocampal cells. The regional specificity in the effect of neural-derived E2 and ERs on the actin polymerization-related pathway may provide a theoretical basis for the functional differences between the hippocampus and prefrontal cortex.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    P1 data, Journal, Combination therapy:  Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. (Pubmed Central) -  Mar 1, 2022   
    P1b
    Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhibitor or fulvestrant in patients with advanced or metastatic breast cancer...Sixty-seven patients were enrolled and received abemaciclib 200 mg every 12 hours in combination with letrozole (Part A, n=20), anastrozole (Part B, n=16), tamoxifen (Part C, n=16), or exemestane (Part D, n=15)...Abemaciclib in combination with multiple endocrine therapy options exhibited manageable safety and promising antitumor activity in patients with HR+, HER2- MBC. https://clinicaltrials.gov/, identifier NCT02057133.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Preparation of smart PVP/HPMC based IPN hydrogel, its characterization and toxicity evaluation. (Pubmed Central) -  Feb 26, 2022   
    Letrozole (LTZ) was loaded as a model drug in the developed system...Acute oral toxicity study depicted no mortality or any signs relating to acute toxicity throughout the whole observed period. Hence, the designed interpenetrating polymeric network might turn out to be a safe and a potential carrier system for the delivery of LTZ in the treatment of breast cancer (BC).
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial initiation date:  NEOLETRIB: Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (clinicaltrials.gov) -  Feb 25, 2022   
    P2,  N=100, Not yet recruiting, 
    Preconception ovarian reserve markers are not associated with preeclampsia and placenta mediated pregnancy complications among women with unexplained infertility who conceive with superovulation with insemination. Initiation date: Jan 2022 --> Apr 2022
  • ||||||||||  letrozole / Generic mfg.
    Trial initiation date:  Letrozole as a Prophylaxis From GTN for Complete Mole Patients (clinicaltrials.gov) -  Feb 23, 2022   
    P2/3,  N=200, Active, not recruiting, 
    Further studies are required to evaluate letrozole alone as an alternative therapy in EPs. Initiation date: Jun 2021 --> Jun 2020
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal, Combination therapy, Real-world evidence:  Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men. (Pubmed Central) -  Feb 23, 2022   
    Real-world data indicated that men with MBC benefit from palbociclib plus ET, with a safety profile consistent with previous observations in women with MBC. Collective data on palbociclib in women and men in this report, including clinical trial data, real-world data, and a well-established risk/benefit profile, led to US approval of an expansion of the palbociclib indication to include men with MBC.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Circulating Liver-enriched Antimicrobial Peptide-2 Decreases During Male Puberty. (Pubmed Central) -  Feb 22, 2022   
    P2/3
    We determined circulating LEAP2 levels in 28 boys with constitutional delay of growth and puberty (CDGP) who participated in a randomized controlled trial (NCT01797718), and were treated with letrozole (n = 15) or intramuscular low-dose testosterone (T) (n = 13) for 6 months...Circulating LEAP2 levels decreased after induction of puberty reciprocally with increased growth rate and energy demand, reflecting the metabolic state of the adolescent. Further, the results suggest that estradiol levels may have a permissive role in downregulating circulating LEAP2 levels.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    A Rare Case of Palbociclib Induced Pneumonitis (Area F, Hall F (North Building, Exhibition Level), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_994;    
    Description: A 67-year-old female with a history of metastatic breast cancer to the bone on Palbociclib (125mg daily) and letrozole (2.5mg daily) for 21 of 28 -day cycles started 2 years ago, presented to the ED with dyspnea, pleuritic chest pain and altered mental status...She again was treated with another course of broad spectrum antibiotics with Vancomycin and Zosyn and finished a 5 days course of Zosyn without much improvement...Initially treated with pulse dose steroids then transitioned to high dose prednisone twice a day...Management includes prompt cessation of Palbociclib, supplemental oxygenation, and high dose corticosteroids. Even though it is a rare side effect, it is important to recognize interstitial pneumonitis as a fatal side effect of Palcociclib.
  • ||||||||||  paclitaxel / Generic mfg.
    Clinical, Retrospective data, Journal:  Evolution of an invasive ductal carcinoma to a small cell carcinoma of the breast: A case report. (Pubmed Central) -  Feb 17, 2022   
    This is a similar pattern of metastases as seen in lung SCC and highlights a potential role for prophylactic cranial irradiation in breast SCC. Further studies are needed to better understand the biology and treatment of breast SCC which continues to present a challenge for clinicians.